Raymond E. Cabillot Sells 6,931 Shares of Pro-Dex, Inc. (NASDAQ:PDEX) Stock

Pro-Dex, Inc. (NASDAQ:PDEXGet Free Report) Director Raymond E. Cabillot sold 6,931 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $45.22, for a total transaction of $313,419.82. Following the completion of the transaction, the director now owns 337,752 shares of the company’s stock, valued at approximately $15,273,145.44. The trade was a 2.01 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Pro-Dex Stock Performance

Shares of PDEX opened at $41.86 on Friday. The company has a market capitalization of $136.46 million, a PE ratio of 27.18 and a beta of 0.56. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.94 and a current ratio of 3.41. The company’s 50 day moving average price is $47.99 and its 200 day moving average price is $33.50. Pro-Dex, Inc. has a 52 week low of $16.18 and a 52 week high of $59.60.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Ritholtz Wealth Management acquired a new stake in shares of Pro-Dex during the 4th quarter valued at about $572,000. Renaissance Technologies LLC lifted its stake in Pro-Dex by 7.9% in the second quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock valued at $240,000 after acquiring an additional 900 shares during the last quarter. FMR LLC grew its position in Pro-Dex by 34.9% in the third quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock worth $119,000 after acquiring an additional 1,028 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Pro-Dex by 9.1% during the 3rd quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock worth $819,000 after purchasing an additional 2,296 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Pro-Dex by 5.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 63,036 shares of the medical instruments supplier’s stock valued at $1,238,000 after purchasing an additional 3,067 shares in the last quarter. 15.28% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently commented on PDEX shares. Ascendiant Capital Markets raised their price objective on shares of Pro-Dex from $30.00 to $52.00 and gave the stock a “buy” rating in a research note on Monday, November 11th. StockNews.com raised Pro-Dex from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 14th.

Get Our Latest Report on Pro-Dex

About Pro-Dex

(Get Free Report)

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.

Recommended Stories

Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.